Novo Nordisk (NYSE: NVO) reported a robust first quarter with a 24% increase in sales at constant exchange rates (CER) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE